- Home
- TPCS vs EXEL Comparison
TPCS vs EXEL Comparison
Compare TPCS & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TPCS | EXEL |
|---|---|---|
| Founded | 1956 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.9M | 11.1B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | TPCS | EXEL |
|---|---|---|
| Price | $4.55 | $44.05 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 24 |
| Target Price | N/A | ★ $45.18 |
| AVG Volume (30 Days) | 31.2K | ★ 2.8M |
| Earning Date | 11-13-2025 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.55 |
| EPS | N/A | ★ 2.38 |
| Revenue | $33,564,000.00 | ★ $2,288,218,000.00 |
| Revenue This Year | N/A | $9.84 |
| Revenue Next Year | N/A | $11.92 |
| P/E Ratio | ★ N/A | $18.64 |
| Revenue Growth | 1.15 | ★ 9.93 |
| 52 Week Low | $2.05 | $31.90 |
| 52 Week High | $6.25 | $49.62 |
Technical Indicators
Market Signals| Indicator | TPCS | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 53.59 | 62.18 |
| Support Level | $4.24 | $40.83 |
| Resistance Level | $4.74 | $42.09 |
| Average True Range (ATR) | 0.24 | 1.15 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 85.51 | 88.38 |
Price Performance
Historical ComparisonAbout TPCS TechPrecision Corporation
Techprecision Corp manufactures metal fabricated and machined precision components and systems. It offers a full range of services required to transform raw materials into precision finished products. The company's products are used in markets including defense, aerospace, nuclear, medical, and precision industries. All of its operations and customers are located in the United States. The company have two wholly owned subsidiaries that are each reportable segments: Ranor and Stadco. Each reportable segment focuses on the manufacture and assembly of specific components. It derives maximum revenue from Ranor segment.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.